Tomer Mark, MD, discusses the emerging role of minimal residual disease as a surrogate end point in multiple myeloma, treatment selection for patients with newly diagnosed, early relapsed, and late relapsed disease, and the importance of daratumumab being introduced to the treatment paradigm of amyloidosis.
Treatment selection for patients with newly diagnosed, early relapsed, and late relapsed multiple myeloma requires consideration of patient-, disease-, and treatment-related factors, said Tomer Mark, MD, who added that the need for minimal residual disease (MRD) as a surrogate end point for survival is stronger now with optimal sequencing strategies remaining uncertain.
Multiple myeloma is moving very fast right now. There are a lot of new agentsthat are exciting, including oral options. There is an embarrassment of riches in terms of treatment for patients with multiple myeloma, so we have to sift through this treasure to find the best treatment for the right patient at the right time, said Mark in an interview with OncLive during an Institutional Perspectives in Cancer (IPC) webinar on multiple myeloma.
During the interview, Mark, an associate professor of medicine, clinical director of the Plasma Cell Disorders Program, and clinical director of the Autologous Stem Cell Transplant Program, in the Department of Medicine-Hematology, at the University of Colorado (UC) School of Medicine, of UCHealth, discussed the emerging role of MRD as a surrogate end point in multiple myeloma, treatment selection for patients with newly diagnosed, early relapsed, and late relapsed disease, and the importance of daratumumab (Darzalex) being introduced to the treatment paradigm of amyloidosis.
Mark: We are seeing the continued theme of MRD and how important it is as an end point. Although not quite universally accepted as a surrogate marker for survival, it certainly is much closer than what we had before with the IMWG [International Myeloma Working Group] criteria. It is good to see that more studies are using MRD as an end point. Also, its good that more patients are reaching that end point, even in the relapsed/refractory setting. We are seeing that in the CAR T-cell therapy studies with idecabtagene vicleucel [ide-cel; Abecma] and ciltacabtagene autoleucel [cilta-cel] that close to 50% of patients are reaching MRD negativity. Extended results with the use of monoclonal antibodies in the up-front setting, like the GRIFFIN study [NCT02874742], also show continued MRD negativity with continued treatment. Getting these very deep responses is the theme now, which is refreshing. Now our problem returns full circle to sequencing, which used to be a big issue a few years ago.
The message is that incorporation of a monoclonal antibody as part of induction therapy provides a great benefit that is durable to patients. Incorporating the monoclonal antibodies [into frontline treatment] is going to become the standard of care. The data we saw at [the 2021 ASH Annual Meeting and Exposition] simply reinforced those results.
The ICARIA-MM [NCT02990338] and IKEMA [NCT03275285] studies looking at isatuximab-irfc [Sarclisa] in combination with either carfilzomib [Kyprolis] or pomalidomide [Pomalyst] showed outstanding results in terms ofnearly a halving of the risk of progression at any point in time. The hazard ratio was between 0.5 and 0.6 in both studies.
Subgroup analyses were refreshing in that age and cytogenetics didnt seem to have much of an effect [on survival] or at least not as much of an effect as they used to with older agents. The theme continues of using monoclonal antibodies early on in therapy. One point to make about that is that sequential CD38-directed antibodies, no matter the order of daratumumab or isatuximab first followed by the other, does not seem to be an effective strategy. There needs to be a period between those sorts of therapies.
That is the major question [in this setting]. There are clinical trials looking at moving CAR T-cell therapy, as well as bispecific antibodies, closer to the frontline [setting]. We are still learning how to manage toxicities from these therapies, like cytokine release syndrome and immune effector cellassociated neurotoxicity syndrome. As we gather more data, these things are getting more predictable and we are managing them better; however, we are keeping patients in the hospital for 2 weeks to get their CAR T cells because we just dont know what will happen. With bispecific antibodies, we have step-up dosing because we just dont know what will happen. We need more experience with these agents.
That said, eventually, CAR T-cell therapy will become part of the standard of care at some point. Just like autologous stem cell transplant, [CAR T-cell therapy] requires some planning, so CAR T-cell therapy may be used in a more elective situation, not as a rescue therapy for patients. Perhaps, the decision will be made based on MRD status after induction. That has yet to be determined.
In emergent situations, we can use bispecific antibodies, which are the off-the-shelf T-cell harnessing therapies. There are practical reasons for using [bispecific antibodies] vs [CAR T-cell therapy].
One nice thing we saw is that we can give sequential antiBCMA-directed therapy, which is the opposite of what we know about [sequential] monoclonal antibodies. That means that we dont have to be as careful in terms of planning whether we are going to give belantamab mafodotin followed by antiBCMA-directed CAR T-cell therapy vs the other way around. Of course, there are some issues with belantamab mafodotin, such as corneal toxicities. The results of belantamab mafodotin in combination with dexamethasone were disappointing, although the later DREAMM trials [evaluating belantamab mafodotin] in combination with bortezomib [Velcade] showed much better results.
It seems that belantamab mafodotin is not destined to be a single-agent therapy and it will be used in combination. It is off-the-shelf, so that is a plus given that we need an ophthalmologic exam before each dose, which is a big minus. In an academic or large hospital where the ophthalmologist is down the hall, that isnt a problem, but in the community clinics where the ophthalmologist is across town, that isnt as practical. These things get baked into the equation.
When we look at comparisons over time, it seems that cilta-cel is a bit more effective than ide-cel. Id like to exercise caution [comparing] apples and oranges. The ide-cel population [comprised] sicker patients in general with higher-risk cytogenetics and higher-risk multiple myeloma. I imagine that if ide-cel were used in a very similar patient population to [the one in which] cilta-cel [was evaluated] this difference might not be so great. We are comparing 2 amazing therapies. For ide-cel, we have seen response rates around 80% with durations of response [DOR] lasting close to 1 year. With cilta-cel, we are looking at 90% to 100% response rates in some studies and a DOR not yet reached.
I get asked this question all the time: Which therapy should I give to give to my patients? The answer is whichever is available. There are manufacturing and supplier problems, as well as slot allocation problems for apheresis and lymphocyte collection. We are grabbing whatever opportunity we get.
It was amazing to perform such a large, randomized trial in AL amyloidosis. I am proud to have participated in this study. It has probably set the world record for the fastest accrual to an amyloidosis trial. That shows the faith that we have in daratumumab working.
The addition of daratumumab to [AL amyloidosis] treatment is probably as significant as the first use of proteasome inhibitors in amyloid treatment. It really is a sea change, and the difference in terms of progression-free survival and organ recovery is so profound that there is no question that daratumumab should be part of frontline care for AL amyloidosis. This is especially [true] for patients who are not transplant eligible.
In transplant-eligible patients, it is more of a question of whether we should transplant patients more up front and then [continue] later with antibody therapy. That is going to be a practical matter in terms of [evaluating] plasma-cell burden, how sick are they, and how many organs are affected. Overall, outcomes for [patients with] amyloidosis are much better now that we have this treatment.
We are working on developing an ex-vivo drug testing platform for patients with multiple myeloma. It is well known that myeloma is not one disease, it is many diseases, which accounts for the variety of outcomes we can see with therapy. This is an effort to tailor the therapy to that patients particular myeloma phenotype, meaning how it behaves in real life. This is opposed to risk-adapted therapy where we make guesses based on high-risk cytogenetics or mutations.
Of course, this only accounts for one aspect of a disease in which there are multiple mutations and clones going on at the same time. Our institution is focused on getting primary patient myeloma samples, real myeloma cells as opposed to cell lines, putting them in cultures with various drugs being tested, and making a prescription for the patient based on this. This is all experimental and more work needs to be done. We are just now doing our translational studies where we are testing this principle out in a clinical trial setting.
See the article here:
Wealth of Newer Treatment Options Span the Scope of Multiple Myeloma and Amyloidosis - OncLive
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
Recent Comments